{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:36:18Z","timestamp":1790742978070,"version":"4.1.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Auton Res"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s10286-021-00839-w","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T10:02:47Z","timestamp":1636538567000},"page":"645-647","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Inhibition of the norepinephrine transporter to treat neurogenic orthostatic hypotension: is this the end of the story?"],"prefix":"10.1007","volume":"31","author":[{"given":"Guillaume","family":"Lamotte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio","family":"Millar Vernetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,10]]},"reference":[{"key":"839_CR1","unstructured":"Biopharma (Theravance Biopharma) (2021) Press release: Thervance Biopharma Inc. Announces Top-line Results from a Phase 3 Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension. https:\/\/www.prnewswire.com\/news-releases\/theravance-biopharma-inc-announces-top-line-results-from-a-phase-3-study-of-ampreloxetine-in-patients-with-symptomatic-neurogenic-orthostatic-hypotension-301377200.html"},{"key":"839_CR2","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/pst.1980","volume":"19","author":"D De Martini","year":"2020","unstructured":"De Martini D (2020) Empowering phase 2 clinical trials to reduce phase 3 failures. Pharm Stat 19:178\u2013186","journal-title":"Pharm Stat"},{"key":"839_CR3","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1001\/jamaneurol.2017.1125","volume":"74","author":"E De Pablo-Fernandez","year":"2017","unstructured":"De Pablo-Fernandez E, Tur C, Revesz T, Lees AJ, Holton JL, Warner TT (2017) Association of autonomic dysfunction with disease progression and survival in Parkinson disease. JAMA Neurol 74:970\u2013976","journal-title":"JAMA Neurol"},{"key":"839_CR4","doi-asserted-by":"publisher","first-page":"e2854","DOI":"10.1212\/WNL.0000000000010749","volume":"95","author":"A Fanciulli","year":"2020","unstructured":"Fanciulli A, Campese N, Goebel G, Ndayisaba JP, Eschlboeck S, Kaindlstorfer C, Raccagni C, Granata R, Bonuccelli U, Ceravolo R, Seppi K, Poewe W, Wenning GK (2020) Association of transient orthostatic hypotension with falls and syncope in patients with Parkinson disease. Neurology 95:e2854\u2013e2865","journal-title":"Neurology"},{"key":"839_CR5","doi-asserted-by":"crossref","unstructured":"Kaufmann H, Vickery R, Wang W, Kanodia J, Shibao CA, Norcliffe-Kaufmann L, Haumann B, Biaggioni I (2021) Safety and efficacy of ampreloxetine in symptomatic neurogenic orthostatic hypotension: a phase 2 trial. Clin Auton Res (online ahead of print)","DOI":"10.1007\/s10286-021-00827-0"},{"key":"839_CR6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10286-020-00681-6","volume":"30","author":"J Martinez","year":"2020","unstructured":"Martinez J, Palma JA, Norcliffe-Kaufmann L, Garakani A, Kaufmann H (2020) Impact of depressive symptoms on self-perceived severity of autonomic dysfunction in multiple system atrophy: relevance for patient-reported outcomes in clinical trials. Clin Auton Res 30:215\u2013221","journal-title":"Clin Auton Res"},{"key":"839_CR7","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1212\/WNL.0000000000005624","volume":"90","author":"J-A Palma","year":"2018","unstructured":"Palma J-A, Mano T (2018) Central or peripheral autonomic dysfunction in Parkinson disease. Does it matter? Neurology 90:1045\u20131046","journal-title":"Neurology"},{"key":"839_CR8","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1055\/s-0040-1713846","volume":"40","author":"JA Palma","year":"2020","unstructured":"Palma JA, Kaufmann H (2020) Clinical trials for neurogenic orthostatic hypotension: a comprehensive review of endpoints, pitfalls, and challenges. Semin Neurol 40:523\u2013539","journal-title":"Semin Neurol"},{"key":"839_CR9","doi-asserted-by":"publisher","first-page":"102721","DOI":"10.1016\/j.autneu.2020.102721","volume":"229","author":"JW Park","year":"2020","unstructured":"Park JW, Okamoto LE, Shibao CA, Biaggioni I (2020) Pharmacologic treatment of orthostatic hypotension. Auton Neurosci 229:102721","journal-title":"Auton Neurosci"},{"key":"839_CR10","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1161\/HYPERTENSIONAHA.114.04225","volume":"64","author":"CE Ramirez","year":"2014","unstructured":"Ramirez CE, Okamoto LE, Arnold AC, Gamboa A, Diedrich A, Choi L, Raj SR, Robertson D, Biaggioni I, Shibao CA (2014) Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure. Hypertension 64:1235\u20131240","journal-title":"Hypertension"},{"key":"839_CR11","first-page":"H1273","volume":"303","author":"C Schroeder","year":"2012","unstructured":"Schroeder C, Jordan J (2012) Norepinephrine transporter function and human cardiovascular disease. Am J Physiol 303:H1273\u2013H1282","journal-title":"Am J Physiol"},{"key":"839_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1161\/HYPERTENSIONAHA.107.089961","volume":"50","author":"C Shibao","year":"2007","unstructured":"Shibao C, Raj SR, Gamboa A, Diedrich A, Choi L, Black BK, Robertson D, Biaggioni I (2007) Norepinephrine transporter blockade with atomoxetine induces hypertension in patients with impaired autonomic function. Hypertension 50:47\u201353","journal-title":"Hypertension"},{"key":"839_CR13","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1161\/HYPERTENSIONAHA.119.14483","volume":"78","author":"CA Shibao","year":"2021","unstructured":"Shibao CA, Palma JA, Celedonio JE, Martinez J, Kaufmann H, Biaggioni I (2021) Predictors of the pressor response to the norepinephrine transporter inhibitor, atomoxetine, in neurogenic orthostatic hypotension. Hypertension 78:525\u2013531","journal-title":"Hypertension"},{"key":"839_CR14","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1136\/archdischild-2013-304037","volume":"98","author":"M Wan","year":"2013","unstructured":"Wan M, Orlu-Gul M, Legay H, Tuleu C (2013) Blinding in pharmacological trials: the devil is in the details. Arch Dis Child 98:656\u2013659","journal-title":"Arch Dis Child"}],"container-title":["Clinical Autonomic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10286-021-00839-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10286-021-00839-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10286-021-00839-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T10:13:29Z","timestamp":1638180809000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10286-021-00839-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,10]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["839"],"URL":"https:\/\/doi.org\/10.1007\/s10286-021-00839-w","relation":{},"ISSN":["0959-9851","1619-1560"],"issn-type":[{"value":"0959-9851","type":"print"},{"value":"1619-1560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,10]]},"assertion":[{"value":"10 November 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Millar Vernetti was a site principal investigator of the Theravance-sponsored clinical trials; he received research funding from Theravance Biopharma. Dr. Lamotte has no conflicts.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}